20/04/2026 – AB Science announced the publication of a new article on the preprint platform medRxiv, evaluating long-term ALS survivors treated with masitinib at 4.5 mg/kg/day in the phase 2b/3 AB10015 study Download PDF Post navigationPreviousPrevious post:Update on clinical development programRelated PostsUpdate on clinical development program16 April 2026AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS24 February 2026FDA granted the status of Minor Use in Major Species (MUMS) for Masivet®9 February 2026AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer29 January 2026AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 204121 January 2026AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia7 January 2026
AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS24 February 2026
AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer29 January 2026
AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 204121 January 2026
AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia7 January 2026
